1.Quality of life improvement in patients diagnosed with hormone refractory prostate cancer with bone metastasis as a result of chemotherapy and the administration of zoledronic acid
Maki Arakawa ; Hiroko Saito ; Takaaki Hasegawa ; Yasuto Kato ; Kiyohito Ishikawa
Palliative Care Research 2008;3(2):308-315
Bone metastases occur in patients who have developed prostate cancer, and severely compromise the patient's quality of life. Here, we evaluated the quality of life in our inpatients diagnosed with prostate cancer with multiple bone metastases and bone pain. In our study, we evaluated pain using a pain diary, investigated the palliative effects of opioid dose, and assessed the quality of life using SF-36. The administration of chemotherapy and zoledronic acid (ZA) resulted in pain palliation, an anti tumor effect and improvements in the quality of life. We suggest that the administration of ZA might be an effective clinical strategy for multimodality advanced solid cancer therapy. We conclude that a 'combined' examination, in which a pain diary evaluating pain is considered in association with an SF-36 assessment evaluating quality of life is crucial to patient care. Palliat Care Res 2008 ; 3(2) : 308-315
2.Effects of maximal exercise on blood leukocyte counts and neutrophil activity in athletes.
KATSUHIKO SUZUKI ; HIDEKI SATO ; TETSU ENDO ; HIROKO HASEGAWA ; MITSUKUNI MOCHIZUKI ; SHIGEYUKI NAKAJI ; KAZUO SUGAWARA ; MANABU TOTSUKA ; KOKI SATO
Japanese Journal of Physical Fitness and Sports Medicine 1996;45(4):451-460
Twenty endurance-trained athletes (five male speed-skaters, eleven male and four female cross-country skiers, 16-18 years) ran on a treadmill by a protocol of incremental graded increase in workload until exhaustion during an endurance training period in off-season summer. Immediately after exercise, all developed peripheral leukocytosis (1.9 times; p<0.01) due mainly to lymphocytosis (2.6 times; p<0.01) with a predominant effect on large granular lymphocyte (natural killer cell) count (5.9 times ; p<0.01) . Monocyte count was also enhanced 2.3 times (p<0.01) . These increases were transitory and returned to the pre-exercise levels 1 h later. Peripheral neutrophilia was also observed by 43% (p<0.01) immediately after exercise and remained elevated by 25% (p<0.01) 1 h after exercise, but a shift to the left did not take place. The capacity of isolated neutrophils to produce reactive oxygen species was assessed by luminol-dependent chemiluminescence which detects mainly myeloperoxidase (MPO) -mediated formation of such hyperreactive oxidants as HOCl. The maximum intensity of chemiluminescence (peak height) upon stimulation with opsonized zymosan was significantly enhanced following exercise (p<0.05) . Similar results were obtained when phorbol myristate acetate was employed as nonphagocytic soluble stimulus (p<0.01), suggesting that the capacity of neutrophils to degranulate MPO rather than phagocytosis was enhanced following exercise. In addition, the enhancements of chemiluminescence were positively correlated with the increase in segmented neutrophil count. These data indicate that maximal exercise not only mobilized mature neutrophils from the marginated pool into the circulation, but also augmented their capacity to generate reactive oxygen species of higher reactivity.
3.The current state of patient education for opioids by doctors, nurses and pharmacists, and evaluation of a pamphlet
Ikuto Kawamura ; Kousuke Kawai ; Yoshitsugu Sano ; Naomi Kubokawa ; Mari Teramachi ; Takashi Mizui ; Yukio Toyama ; Hiroko Saito ; Takaaki Hasegawa
Palliative Care Research 2009;4(1):214-227
The first step of cancer medical treatment is to eliminate anxiety about opioids. It is recommended to use printed matter in the "Guideline for Cancer Pain Management" edited by Japanese Society of Palliative Medicine,but few medical professionals actually use it. We developed the Opioids' pamphlet designed by Aichi Prefectural Society of Hospital Pharmacists; abbreviated OPA. This pamphlet is little burdened for readers; focusing on eliminating anxiety about opioids. Evaluation of the utility of the OPA and the actual conditions of patient education about the use of opioids by medical professionals were investigated, since there have been no reports on these issues. A questionnaire survey was conducted in hospitals with more than 150 beds in Aichi Prefecture. It targeted doctors, pharmacists and nurses who were practicing palliative care using opioids. There were many pharmacists and nurses who had been consulted about opioids, and most of the consultations were about addiction. 60% of pharmacists and 30% of nurses voluntarily performed patient education. Awareness of the guideline for of cancer pain management was low. OPA, which was reviewed based on the guideline, was applicable to 99% of the cases where the nurses were consulted. Its size and contents were highly acclaimed. Therefore, OPA is extremely valuable in clinical practice. Palliat Care Res 2009; 4(1): 214-227
4.Evaluation of the effect of analgesics for cancer patients using their pain descriptions
Kikuyo Nishida ; Yukio Toyama ; Kumi Kuno ; Shigeki Hirano ; Yuko Deguchi ; Yuiko Matsuda ; Takashi Watanabe ; Chie Yamazeki ; Yukari Itakura ; Hiroko Saito ; Takaaki Hasegawa
Palliative Care Research 2009;4(1):207-213
Purpose: The present study aims to evaluate the effect of analgesics in cancer patients based on their pain descriptions. Methods: The relationship between the words that patients used to describe their pain due to cancer and the efficacy of treatment with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) or opioids was evaluated. Results: We recorded 529words that were used by 164patients to describe their pain and pain quality and classified them into 108types of pain.For patients who used the actual word 'dull' or one with a similar meaning, treatment with opioids was effective. However, treatment with opioids was less effective in patients who used words such as "numb" and "tingling". Conclusion: We were able to gain a good understanding of cancer pain by listening to the actual words that patients used when complaining of pain. These findings suggested that we could choose a suitable medication through evaluation of the actual words cancer patients used to describe their pain and successfully relieve their pain. Palliat Care Res 2009: 4(1): 207-213
5.A Survey on Effects of Caffeine in Psychiatric Outpatients
Erika DEGAWA ; Takahito ANDO ; Masazumi ANDO ; Tsuyoshi KATO ; Toshi SHIMAMURA ; Akane NAGATA ; Tetsuo MURANO ; Hiroaki HAYASHI ; Hiroko BABA ; Moemi SAITO
Japanese Journal of Drug Informatics 2018;20(3):189-199
Objective: Caffeine may cause dependence and sleep disturbance, and interact with psychotropic drugs. Therefore, the caffeine intake of patients with mental disorders should be monitored. However, in Japan, there is no report on the effects of caffeine in mental disease patients or on their caffeine intake. Therefore, we conducted a questionnaire survey to clarify the perception of caffeine for psychiatric outpatients.Methods: We conducted an anonymous survey on caffeine recognition for outpatients at 8 medical institutions that advocate psychiatry.Results: We collected questionnaires from 180 people. The knowledge of foods containing caffeine tended to be high in those who had a positive attitude toward caffeine. More than 90% of those surveyed knew that coffee contains caffeine, but cocoa and jasmine tea were recognized by less than 25%. Of those surveyed, 39.4% consumed caffeine‐containing beverages at night. In addition, the rate of consumption of caffeine‐containing beverages tended to be higher at night because they had a positive attitude toward caffeine.Conclusion: The knowledge and intake situation of caffeine by patients with mental disorders differed depending on their interests and way of thinking about caffeine. As caffeine intake may influence psychiatric treatment, correct knowledge regarding caffeine is important.
6.Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer
Aikou OKAMOTO ; Eiji KONDO ; Toshiaki NAKAMURA ; Satoshi YANAGIDA ; Junzo HAMANISHI ; Kenichi HARANO ; Kosei HASEGAWA ; Takeshi HIRASAWA ; Kensuke HORI ; Shinichi KOMIYAMA ; Motoki MATSUURA ; Hidekatsu NAKAI ; Hiroko NAKAMURA ; Jun SAKATA ; Tsutomu TABATA ; Kazuhiro TAKEHARA ; Munetaka TAKEKUMA ; Yoshihito YOKOYAMA ; Yoichi KASE ; Shuuji SUMINO ; Junpei SOEDA ; Ajit SURI ; Daisuke AOKI ; Toru SUGIYAMA
Journal of Gynecologic Oncology 2021;32(2):e16-
Objective:
To evaluate the efficacy and safety of niraparib in Japanese women with heavily pretreated ovarian cancer.
Methods:
This Phase 2 open-label, single-arm study enrolled Japanese women with homologous recombination deficiency-positive relapsed, high-grade serous ovarian, fallopian tube, or primary peritoneal cancer who had completed 3–4 lines of therapy. The starting dose of niraparib was 300 mg administered once daily in continuous 28-day cycles until objective progressive disease, unacceptable toxicity, consent withdrawal or discontinuation. The primary endpoint, objective response rate (ORR), was assessed by the investigator using RECIST version 1.1. Safety evaluations included the incidence of treatment-emergent adverse events (TEAEs), including serious TEAEs.
Results:
Twenty women were enrolled and the confirmed ORR in the full analysis set (FAS) was 35.0% (7/20), consisting of 1 complete response and 6 partial responses. Disease control rate in the FAS was 90.0%. The most frequently reported TEAEs (>50%) were anemia, nausea, and platelet count decreased. One patient (5.0%) had TEAEs leading to discontinuation of niraparib whereas reductions or interruptions were reported in 14 (70.0%) and 15 (75.0%) patients, respectively. The median dose intensity (202.9 mg daily) corresponded to a relative dose intensity of 67.6%.
Conclusion
Efficacy and safety of niraparib in heavily pretreated Japanese women was comparable to that seen in an equivalent population of non-Japanese women. No new safety signals were identified.
7.Clinical utility of CA-125 in the management of uterine carcinosarcoma.
Koji MATSUO ; Malcolm S ROSS ; Mayu YUNOKAWA ; Marian S JOHNSON ; Hiroko MACHIDA ; Kohei OMATSU ; Merieme M KLOBOCISTA ; Dwight D IM ; Shinya SATOH ; Tsukasa BABA ; Yuji IKEDA ; Stephen H BUSH ; Kosei HASEGAWA ; Erin A BLAKE ; Munetaka TAKEKUMA ; Masako SHIDA ; Masato NISHIMURA ; Sosuke ADACHI ; Tanja PEJOVIC ; Satoshi TAKEUCHI ; Takuhei YOKOYAMA ; Yutaka UEDA ; Keita IWASAKI ; Takahito M MIYAKE ; Shiori YANAI ; Tadayoshi NAGANO ; Tadao TAKANO ; Mian MK SHAHZAD ; Frederick R UELAND ; Joseph L KELLEY ; Lynda D ROMAN
Journal of Gynecologic Oncology 2018;29(6):e88-
No abstract available.
Carcinosarcoma*